Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06692894 · ClinicalTrials.gov registry record
Defining Inflammatory Markers of Cardiovascular Disease in Patients With Myelodysplastic Syndromes
A clinical trial of Myelodysplastic Syndromes, Adult, sponsored by University of Vermont.
- Recruiting
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT06692894: Recruiting study of Myelodysplastic Syndromes, Adult, sponsored by University of Vermont.
NCT06692894 is a study of Myelodysplastic Syndromes, Adult that is actively recruiting participants, run by University of Vermont. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06692894, a study of Myelodysplastic Syndromes, Adult, is actively recruiting participants, sponsored by University of Vermont.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Why Is This Research Study Being Conducted? * The study wants to find out why people with a type of blood cancer called myelodysplastic syndromes (MDS) are more likely to have heart problems like heart disease and stroke. * Researchers also want to see if certain proteins related to inflammation in the body can help predict these heart issues in MDS patients. * By understanding this better, researchers hope to find new ways to detect and manage heart disease risks in people with MDS
Primary Outcome
The within- and between-person biologic variability of an inflammation proteome over a period of 6 months
Conditions Studied
Interventions
- OTHER Observational
Study Locations (1)
Vermont
- University of Vermont - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-11-05 |
| Est. Completion | 2027-11 |
What NCT06692894 shows while recruiting
NCT06692894 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 1 condition, with Myelodysplastic Syndromes, Adult appearing as the primary indexed condition, and to 1 intervention - of which Observational is the first listed.
NCT06692894 reports a single indexed study location in Vermont.
Frequently Asked Questions
What is clinical trial NCT06692894 about?
NCT06692894 is a clinical study titled "Defining Inflammatory Markers of Cardiovascular Disease in Patients With Myelodysplastic Syndromes". Why Is This Research Study Being Conducted? * The study wants to find out why people with a type of blood cancer called myelodysplastic syndromes (MDS) are more likely to have heart problems like heart disease and stroke. * Researchers also want to see if certain proteins related to inflammation in...
What is the current status of trial NCT06692894?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2024-11-05. Estimated completion is 2027-11.
What conditions does trial NCT06692894 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes, Adult.
What interventions are being tested in trial NCT06692894?
The interventions under investigation include: Observational (OTHER).
Who is sponsoring clinical trial NCT06692894?
This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06692894 being conducted?
This trial has 1 study location across Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI